Evidence-based practice guideline of Chinese herbal medicine for primary open-angle glaucoma (qingfeng -neizhang)

Yang, Yingxin; Ma, Qiuyan; Yang, Yue; He, Yiping; Ma, Chao-Ting; Li, Qiang; Jin, Ming; Chen, Wei

doi:10.1097/md.0000000000010126

Cited by 70 publications

(18 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…POAG is the most common of glaucoma, which often results in vision loss [1][2][3][4]. The management approach of DTFC becomes very important in treating POAG.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Can dorzolamide/timolol-fixed combination effectively treat primary open-angle glaucoma? A protocol for systematic review and meta-analysis

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Primary open-angle glaucoma (POAG) is a very common disorder, and it is the second leading reason that leads to blindness worldwide after cataracts. Previous studies have reported that dorzolamide/timolol-fixed combination (DTFC) can be used to treat patients with POAG. However, there are still inconsistent results. Thus, this study will systematically investigate the efficacy and safety of DTFC for the treatment of patients with POAG.Methods: A comprehensive search will be carried out in the electronic databases of Cochrane Library, MEDLINE, EMBASE, CINAHI, ACMD, China National Knowledge Infrastructure, and Wanfang Data from origin to the March 1, 2020. There are no limitations related to the language and publication status. Only randomized controlled trials that assessed the efficacy and safety of DTFC for the treatment of POAG will be included. Two researchers will independently undertake record selection, data extraction, and methodological quality assessment. Any divisions will be solved by discussion with a third researcher. We will perform statistical analysis using RevMan 5.3 softwareDiscussion: This study will summarize present evidence to identify the efficacy and safety of DTFC for the treatment of POAG through mean intraocular pressure, best corrected visual acuity, contrast sensitivity, bioelectric activity of the retina, rate of progression of glaucoma, quality of life, and adverse events. The results of this study will help to determine whether DTFC is effective and safety for the treatment of POAG.Systematic review registration: INPLASY202040120.

show abstract

“…POAG is the most common of glaucoma, which often results in vision loss [1][2][3][4]. The management approach of DTFC becomes very important in treating POAG.…”

Section: Discussionmentioning

confidence: 99%

“…Primary open-angle glaucoma (POAG) is the most types of glaucoma [1][2][3][4]. It is associated with elevated intraocular pressure (IOP) and damage to the optic nerve [4][5], which nally results in irreversible vision loss [6][7][8][9]. Conventional managements mainly focus on lowering IOP [10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Can dorzolamide/timolol-fixed combination effectively treat primary open-angle glaucoma? A protocol for systematic review and meta-analysis

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Traditional Chinese medicine (TCM) therapy has been used to treat glaucoma for thousands of years and has demonstrated a more favorable safety profile than conventional medicine [5,6]. In TCM, the same disease could be diagnosed as comprising various syndromes.…”

Section: Background and Rationale {6a}mentioning

confidence: 99%

“…All eligible participants should meet the following criteria: (1) diagnosed with primary open-angle glaucoma (POAG) [13]: pathologic high intraocular pressure (HIOP; 24 h peak IOP > 21 mmHg (1 mmHg = 0.133 kPa), characteristic glaucomatous neuropathy (RNFL defect or optic disc change), and/or visual field loss, open anterior chamber angle, exclusion of other causes result in HIOP, only one eye from each patient will be chosen; (2) have a visual field defect that could be evaluated by standard automated perimetry (reliability factor < 15%) and an IOP that is < 18 mmHg (at least 3 months after anti-glaucoma surgery); (3) meet the syndrome pattern of kidney deficiency and blood stasis; (4) withdraw from using other optic nerve protective agents for > 2 months; (5) have spherical refractive error between + 3.00 and − 6.00 diopters, clearly visible fundus without pupil dilation, and best-corrected visual acuity (BCVA) ≥ 0.3; (6) be aged 18-75 years; (7) be in a conscious status and able to cooperate with the examination and treatment; and (8) be willing to take part in the study and sign informed consent.…”

Section: Eligibility Criteria {10} Inclusion Criteriamentioning

confidence: 99%

Efficacy and safety of Bujing Yishi tablet for glaucoma with controlled IOP: study protocol for a multi-centre randomized controlled trial

Liu

Zhang

et al. 2020

Trials

View full text Add to dashboard Cite

Background As an irreversible, intractable disease with vision loss, glaucoma leads to permanent and progressive damage of visual function. Lowering high intraocular pressure (HIOP) is the first choice for treating glaucoma; however, the control of HIOP is not enough to prevent progressive vison loss. Currently, the therapies to treat glaucoma with controlled IOP (GPCI) are unsatisfactory. Chinese medicine is effective for improving visual function in patients with GPCI. Bujing Yishi tablets (BJYSP) have been the standard preparation for treating GPCI in our hospital for decades. However, no rigorous randomized controlled clinical studies have investigated its effects and safety. Methods This study will be a 6-month, multicenter, stratified trial following a prospective, randomized, open-label, blinded endpoint (PROBE) protocol. A total of 216 eligible GPCI patients aged 18–75 years will be stratified according to the early, moderate, and advanced stages of glaucoma. After stratifying, the participants will be randomly assigned to the BJYSP group or control group at a ratio of 1:1. Following randomization, participants in the BJYSP group and control group will receive BJYSP and mecobalamin tablets, respectively, for the same 6-month period. The primary outcomes will include the best-corrected visual acuity (BCVA), visual field assessment, visual evoked potential (VEP) test, and Heidelberg retina tomography II (HRT II); the secondary outcomes will include intraocular pressure (IOP) and Traditional Chinese medicine (TCM) clinical symptom scales. The primary and secondary outcomes will be measured at baseline and 8, 16, and 24 weeks thereafter. Safety assessments will also be evaluated at baseline and 12 and 24 weeks thereafter. Discussion This study will be a standardized, scientific, clinical trial designed to evaluate the therapeutic effects and safety of BJYSP as a novel therapeutic strategy for improving visual function in patients with GPCI. Trial registration Chinese Clinical Trial Registry, ChiCTR1800016431. Registered on 1 June 2018.

show abstract

“…This dosing requirement in addition to other well-known side-effects has prevented cannabis in its current form from becoming a treatment of choice for glaucoma. Chinese herbal medicine for the treatment of primary open-angle glaucoma is yet another interesting option pending an examination of evidence-based practice guidelines [18]. Traditional Chinese medicine focuses on the patient's entire body rather than targeting specific organs.…”

Section: New Pharmaceutical Approaches To Treat Glaucoma and New Waysmentioning

confidence: 99%

Influence of new treatment modalities on adherence in glaucoma

Meier-Gibbons

Berlin

Töteberg‐Harms

2019

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

PURPOSE OF REVIEW It is well known that glaucoma patients are not adherent to their therapeutic regimens. The issue of nonadherence is multifactorial and includes inadequate communication between doctors and patients, resulting in significant costs associated with enhanced disease progression. Therapeutic regimens are risk factors which often influences adherence rates. Thus, alternative treatment modalities, especially those risk factors that do not rely on patients' cooperation, may enable improvements in long-term outcomes of glaucoma in patient. RECENT FINDINGS The studies selected for this review were divided into new medications, especially advancements in pharmaceutical approaches to treat glaucoma and new ways of delivering the medication, new surgical methods, especially minimally invasive surgery methods for glaucoma, and new studies about adherence in glaucoma. SUMMARY Surprisingly, a very few studies on glaucoma medication or surgery addressed the concept of adherence. However, adherence is discussed in studies which consider psychological aspects of patients or communication issues between doctors and patients. Although these studies were performed in clinical settings, the issue of adherence is not addressed; despite it has significant effect on long-term outpatient care. A combination of both aspects, adherence and miscommunication, should be considered in studies.

show abstract

Evidence-based practice guideline of Chinese herbal medicine for primary open-angle glaucoma (qingfeng -neizhang)

Abstract: Supplemental Digital Content is available in the text

Cited by 70 publications

References 1 publication

Can dorzolamide/timolol-fixed combination effectively treat primary open-angle glaucoma? A protocol for systematic review and meta-analysis

Can dorzolamide/timolol-fixed combination effectively treat primary open-angle glaucoma? A protocol for systematic review and meta-analysis

Efficacy and safety of Bujing Yishi tablet for glaucoma with controlled IOP: study protocol for a multi-centre randomized controlled trial

Influence of new treatment modalities on adherence in glaucoma

Contact Info

Product

Resources

About